Samsung Biologics, a South Korea-based contract development and manufacturing organisation (CDMO), has partnered with LegoChem Biosciences to develop and manufacture antibodies as a part of the latter’s ADC programme designed to treat solid tumours.

LegoChem is a clinical-stage biopharmaceutical company engaged in the research and development of antibody-drug conjugate (ADC) programmes.

The company will submit an investigational new drug (IND) application to the US Food and Drug Administration (FDA) in the first half of 2025.

The IND submission will be supported by promising non-clinical data and efficacy results.

LegoChem Biosciences CEO and president Yong-Zu Kim said: “LegoChem Biosciences had previously supplied antibodies for ADC through only overseas companies, but we expect that we will be able to secure a stable domestic supply chain through this contract.”

Samsung Biologics also intends to add ADC to its pipeline, with the construction of a standalone, dedicated ADC facility expected to be operational within 2024.

Building on its expertise in antibody engineering, process development, and large-scale manufacturing, the company will offer complete ADC development and manufacturing services.

The company is also making active investments in biotech companies focusing on ADC linker technologies, through its Samsung Life Science Fund.

Samsung Biologics CEO and president John Rim said: “Collaboration between Samsung Biologics and LegoChem Biosciences will enable us to deliver on our common goal to develop and manufacture efficient and safe therapeutics for patients.

“We look forward to working with LegoChem Biosciences to support their pipeline of innovative ADC candidates and secure new opportunities in the fast-growing ADC field.”

In July last year, the CDMO signed two deals worth $897m with Pfizer to manufacture Pfizer’s biosimilar products from oncology and inflammation to immunotherapy until 2029 at its new plant in South Korea.